An Evolving Landscape: New Therapies for Metastatic Colorectal Cancer

被引：0
作者：
Mo, Christiana [1 ,2 ]
Chadha, Bhawneet [1 ,2 ]
Kuang, Chaoyuan [1 ,3 ]
机构：
[1] Montefiore Einstein, Dept Oncol, Bronx, NY USA
[2] Montefiore Einstein Comprehens Canc Ctr, Bronx, NY USA
[3] Montefiore Einstein, Dept Mol Pharmacol, Bronx, NY USA
来源：
CLINICAL COLORECTAL CANCER | 2024年 / 23卷 / 04期
关键词：
Immunotherapy; Targeted therapy; Colorectal cancer; Chemotherapy; Clinical trials; CETUXIMAB PLUS IRINOTECAN; OPEN-LABEL; 1ST-LINE TREATMENT; SUBGROUP ANALYSES; DOUBLE-BLIND; SINGLE-ARM; PHASE-II; MULTICENTER; SURVIVAL; PLACEBO;
D O I：
10.1016/j.clcc.2024.08.003
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Substantial progress is being made in the development of novel therapies directed against colorectal cancer. The discovery of various molecular markers and advances in tumor profiling have facilitated the development of new targeted agents and immunotherapy. Not only have these drugs improved progression-free survival and even overall survival in some cases, but their related outcomes have also raised questions as to how to best combine or sequence therapies for even greater efficacy. Furthermore, we are beginning to understand how these combination therapies may yield for greater therapeutic response for patients with microsatellite stable colorectal cancer for which there is much need for improvement. In this article, we review recent trial data and explore the outcomes of various targeted therapies and immunotherapies for patient with advanced colorectal cancer.
引用
收藏
页码：337 / 345
页数：9
相关论文
共 69 条
  • [1] EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer
    Amodio, Vito
    Yaeger, Rona
    Arcella, Pamela
    Cancelliere, Carlotta
    Lamba, Simona
    Lorenzato, Annalisa
    Arena, Sabrina
    Montone, Monica
    Mussolin, Benedetta
    Bian, Yu
    Whaley, Adele
    Pinnelli, Marika
    Murciano-Goroff, Yonina R.
    Vakiani, Efsevia
    Valeri, Nicola
    Liao, Wei-Li
    Bhalkikar, Anuja
    Thyparambil, Sheeno
    Zhao, Hui-Yong
    de Stanchina, Elisa
    Marsoni, Silvia
    Siena, Salvatore
    Bertotti, Andrea
    Trusolino, Livio
    Li, Bob T.
    Rosen, Neal
    Di Nicolantonio, Federica
    Bardelli, Alberto
    Misale, Sandra
    [J]. CANCER DISCOVERY, 2020, 10 (08) : 1129 - 1139
  • [2] Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): First results of the CheckMate 8HW study
    Andre, Thierry
    Elez, Elena
    Van Cutsem, Eric
    Jensen, Lars Henrik
    Bennouna, Jaafar
    Mendez, Guillermo
    Schenker, Michael
    De La Fouchardiere, Christelle
    Limon, Maria Luisa
    Yoshino, Takayuki
    Li, Jin
    Lenz, Heinz-Josef
    Manzano Mozo, Jose Luis
    Tortora, Giampaolo
    Garcia-Carbonero, Rocio
    Cela, Elvis
    Yang, Yingsi
    Lei, Ming
    Jin, Lixian
    Lonardi, Sara
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : LBA768 - LBA768
  • [3] Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial
    Andre, Thierry
    Amonkar, Mayur
    Norquist, Josephine M.
    Shiu, Kai-Keen
    Kim, Tae Won
    Jensen, Benny Vittrup
    Jensen, Lars Henrik
    Punt, Cornelis J. A.
    Smith, Denis
    Garcia-Carbonero, Rocio
    Sevilla, Isabel
    de la Fouchardiere, Christelle
    Rivera, Fernando
    Elez, Elena
    Diaz Jr, Luis A.
    Yoshino, Takayuki
    Cutsem, Eric Van
    Yang, Ping
    Farooqui, Mohammed
    Le, Dung T.
    [J]. LANCET ONCOLOGY, 2021, 22 (05) : 665 - 677
  • [4] Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial
    Antoniotti, Carlotta
    Rossini, Daniele
    Pietrantonio, Filippo
    Catteau, Aurelie
    Salvatore, Lisa
    Lonardi, Sara
    Boquet, Isabelle
    Tamberi, Stefano
    Marmorino, Federica
    Moretto, Roberto
    Ambrosini, Margherita
    Tamburini, Emiliano
    Tortora, Giampaolo
    Passardi, Alessandro
    Bergamo, Francesca
    Kassambara, Alboukadel
    Sbarrato, Thomas
    Morano, Federica
    Ritorto, Giuliana
    Borelli, Beatrice
    Boccaccino, Alessandra
    Conca, Veronica
    Giordano, Mirella
    Ugolini, Clara
    Fieschi, Jacques
    Papadopulos, Alexia
    Massoue, Clementine
    Aprile, Giuseppe
    Antonuzzo, Lorenzo
    Gelsomino, Fabio
    Martinelli, Erika
    Pella, Nicoletta
    Masi, Gianluca
    Fontanini, Gabriella
    Boni, Luca
    Galon, Jerome
    Cremolini, Chiara
    [J]. LANCET ONCOLOGY, 2022, 23 (07) : 876 - 887
  • [5] Acquired Resistance to KRASG12C Inhibition in Cancer
    Awad, M. M.
    Liu, S.
    Rybkin, I. I.
    Arbour, K. C.
    Dilly, J.
    Zhu, V. W.
    Johnson, M. L.
    Heist, R. S.
    Patil, T.
    Riely, G. J.
    Jacobson, J. O.
    Yang, X.
    Persky, N. S.
    Root, D. E.
    Lowder, K. E.
    Feng, H.
    Zhang, S. S.
    Haigis, K. M.
    Hung, Y. P.
    Sholl, L. M.
    Wolpin, B. M.
    Wiese, J.
    Christiansen, J.
    Lee, J.
    Schrock, A. B.
    Lim, L. P.
    Garg, K.
    Li, M.
    Engstrom, L. D.
    Waters, L.
    Lawson, J. D.
    Olson, P.
    Lito, P.
    Ou, S. -H. I.
    Christensen, J. G.
    Janne, P. A.
    Aguirre, A. J.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (25) : 2382 - 2393
  • [6] Bekaii-Saab TS, 2023, J CLIN ONCOL, V41, pTPS261
  • [7] Impact of Anti-EGFR Therapies on HER2-Positive Metastatic Colorectal Cancer: A Systematic Literature Review and Meta-Analysis of Clinical Outcomes
    Bekaii-Saab, Tanios S.
    Lach, Krzysztof
    Hsu, Ling-, I
    Siadak, Muriel
    Stecher, Mike
    Ward, James
    Beckerman, Rachel
    Strickler, John H.
    [J]. ONCOLOGIST, 2023, 28 (10) : 885 - 893
  • [8] Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC
    Cho, Byoung C.
    Lu, Shun
    Felip, Enriqueta
    Spira, Alexander I.
    Girard, Nicolas
    Lee, Jong-Seok
    Lee, Se-Hoon
    Ostapenko, Yurii
    Danchaivijitr, Pongwut
    Liu, Baogang
    Alip, Adlinda
    Korbenfeld, Ernesto
    Mourao Dias, Josiane
    Besse, Benjamin
    Lee, Ki-Hyeong
    Xiong, Hailin
    How, Soon-Hin
    Cheng, Ying
    Chang, Gee-Chen
    Yoshioka, Hiroshige
    Yang, James C. -H.
    Thomas, Michael
    Nguyen, Danny
    Ou, Sai-Hong I.
    Mukhedkar, Sanjay
    Prabhash, Kumar
    D'Arcangelo, Manolo
    Alatorre-Alexander, Jorge
    Vazquez Limon, Juan C.
    Alves, Sara
    Stroyakovskiy, Daniil
    Peregudova, Marina
    Sendur, Mehmet A. N.
    Yazici, Ozan
    Califano, Raffaele
    Gutierrez Calderon, Vanesa
    de Marinis, Filippo
    Passaro, Antonio
    Kim, Sang-We
    Gadgeel, Shirish M.
    Xie, John
    Sun, Tao
    Martinez, Melissa
    Ennis, Mariah
    Fennema, Elizabeth
    Daksh, Mahesh
    Millington, Dawn
    Leconte, Isabelle
    Iwasawa, Ryota
    Lorenzini, Patricia
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2024, 391 (16) : 1486 - 1498
  • [9] MARIPOSA: phase 3 study of first-line amivantamab plus lazertinib versus osimertinib in EGFR-mutant non-small cell lung cancer
    Cho, Byoung Chul
    Felip, Enriqueta
    Hayashi, Hidetoshi
    Thomas, Michael
    Lu, Shun
    Besse, Benjamin
    Sun, Tao
    Martinez, Melissa
    Sethi, Seema N.
    Shreeve, S. Martin
    Spira, Alexander, I
    [J]. FUTURE ONCOLOGY, 2022, 18 (06) : 639 - 647
  • [10] Colicelli John, 2004, Sci STKE, V2004, pRE13, DOI 10.1126/stke.2502004re13
1234567